GlassScriptPhysician profile
Gerzain Chavez
NPI 1194837120
$2,624.63
in general payments reported to CMS, 2019-2025
25 companies · $36.57 in 2025
The $36.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $991 · 2021: $233 · 2022: $52.41 · 2023: $14.66 · 2024: $203 · 2025: $36.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $505.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.48 | 2019-2021 | |
| Amgen INC. | $263.44 | 2019-2021 | |
| Pfizer INC. | $236.15 | 2019-2022 | |
| Lilly USA, LLC | $200.34 | 2019-2021 | |
| Becton, Dickinson and Company | $139.33 | 2024 | Bd Max System, Bd Max Instrument |
| Janssen Pharmaceuticals, INC | $131.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $116.43 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $93.65 | 2019-2021 | |
| Novo Nordisk INC | $83.99 | 2019-2021 | |
| Amarin Pharma, INC. | $64.28 | 2020 | |
| Exact Sciences Corporation | $62.42 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $59.03 | 2019 | |
| Glaxosmithkline, LLC. | $43.48 | 2019-2023 | Shingrix |
| Biohaven Pharmaceuticals, INC. | $40.34 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $37.09 | 2020 | |
| Therapeuticsmd, INC. | $24.89 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Neurocrine Biosciences, INC. | $19.33 | 2024 | Ingrezza |
| Abbvie INC. | $19.13 | 2019 | |
| Abbott Laboratories | $18.97 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $15.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.54 | 2021 | |
| Allergan, INC. | $14.09 | 2020 | |
| Sanofi Pasteur INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerzain Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.